1. Home
  2. FSUN vs URGN Comparison

FSUN vs URGN Comparison

Compare FSUN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSUN

FirstSun Capital Bancorp

HOLD

Current Price

$38.36

Market Cap

966.0M

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$23.03

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSUN
URGN
Founded
1892
2004
Country
United States
United States
Employees
N/A
253
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
966.0M
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FSUN
URGN
Price
$38.36
$23.03
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$46.33
$28.50
AVG Volume (30 Days)
138.6K
773.4K
Earning Date
01-26-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
3.52
N/A
EPS
3.16
N/A
Revenue
$384,497,000.00
$96,516,000.00
Revenue This Year
$19.09
$27.96
Revenue Next Year
$62.50
$123.20
P/E Ratio
$12.14
N/A
Revenue Growth
10.48
8.00
52 Week Low
$29.95
$3.42
52 Week High
$45.32
$30.00

Technical Indicators

Market Signals
Indicator
FSUN
URGN
Relative Strength Index (RSI) 61.72 48.71
Support Level $37.13 $22.60
Resistance Level $40.07 $24.14
Average True Range (ATR) 1.06 1.17
MACD 0.10 -0.09
Stochastic Oscillator 64.32 49.09

Price Performance

Historical Comparison
FSUN
URGN

About FSUN FirstSun Capital Bancorp

Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: